for an evaluation of the clinical utility of prostate-specific antigen ( psa ) , 32 prostatic carcinoma patients ( ages 54-76 ) and 13 nonprostatic carcinoma patients ( ages 60-70 ) underwent psa measurements and bone imaging .
C0138741
prostate-specific antigen
C0600139
prostatic carcinoma